Seven GLP-1 Agonists Compared for Weight Loss Efficacy

Obesity and overweight are global health crises, significantly increasing the risk of conditions like type 2 diabetes, cardiovascular disease, and certain cancers. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and polyagonists (drugs that activate multiple hormone receptors, like GLP-1 and GIP) have emerged as highly effective treatments for weight management. However, with several new agents available, there's a critical need to systematically compare the relative efficacy of these different GLP-1-based therapies for weight loss.

The network meta-analysis revealed significant differences in weight loss efficacy among the seven GLP-1 RAs and polyagonists. Certain polyagonists demonstrated superior weight loss compared to single GLP-1 RAs, indicating a clear advantage for multi-receptor targeting. The study identified specific agents as most effective for achieving substantial body weight reduction. The analysis concluded that tirzepatide (a GLP-1/GIP co-agonist) was significantly more effective for weight loss than other GLP-1 RAs, showing the greatest magnitude of body weight reduction across the included trials. Other agents like semaglutide also showed strong efficacy, consistently outperforming placebo and several older GLP-1 RAs. The findings suggest a clear hierarchy of efficacy, with newer polyagonists generally providing better outcomes than older, single-target GLP-1 RAs, offering a greater average percentage of total body weight loss.